LGND up +3.50% percent Today $LGND High is at 57.7
Post# of 48
Posted On: 11/11/2014 12:42:04 PM
LGND up +3.50% percent Today $LGND High is at 57.76 and the Low 55.60 with current volume of 160,705.
Recent News posted below.
Ligand Pharmaceuticals Inc LGND other info.
http://investorshangout.com/Ligand-Pharmaceut...GND-54621/
LGND Ligand Pharmaceuticals Inc Recent Headline News
Shares of LGND Up 13.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - 2 hrs 18 mins ago
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 4 weeks, Ligand Pharmaceuticals has returned 13.91% as of today's recent price of $55.64.
LGND: 58.26 (+2.58)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), ACHN: 13.04 (+0.19), CNAT: 7.06 (unch), MRK: 59.57 (+0.76), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.41 (-0.73)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), ACHN: 13.04 (+0.19), CNAT: 7.06 (unch), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Post Earnings Update: Ligand Pharmaceuticals Has Sunk 0.5% Lower in Past 2 Weeks (LGND)
Comtex SmarTrend(R) - Mon Nov 10, 11:52AM CST
When Ligand Pharmaceuticals (NASDAQ:LGND) reported earnings 14 days ago on October 27th, 2014, analysts, on average, expected the company to report earnings of $0.33 on sales of $14.9 million. The company actually reported EPS of $0.06 on sales of $15.0 million, missing EPS estimates by $0.27 and matching revenue estimates. Shares of Ligand Pharmaceuticals have slipped from $54.23 to $53.94, representing a loss of 0.5%, since the company reported earnings 14 days ago.
LGND: 58.26 (+2.58)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), ACHN: 13.04 (+0.19), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Ligand Pharmaceuticals Shares Up 12.9% Since SmarTrend's Buy Recommendation (LGND)
Comtex SmarTrend(R) - Mon Nov 03, 10:02AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 2 weeks, Ligand Pharmaceuticals has returned 12.89% as of today's recent price of $55.14.
LGND: 58.26 (+2.58)
Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) reported higher third-quarter earnings of 19 cents per share but fell short of the Zacks Consensus Estimate by 2 cents.
BIIB: 326.81 (-1.06), LGND: 58.26 (+2.58), AMGN: 163.25 (+0.16), GSK: 45.80 (+0.64)
Ligand Pharmaceuticals Has Rich A Valuation Now But Is Undervalued For Long Term Success
Chris Katje - at Seeking Alpha - Wed Oct 29, 10:34AM CDT
PFE: 30.20 (unch), AZN: 74.23 (+1.02), LGND: 58.26 (+2.58), AMGN: 163.25 (+0.16), GSK: 45.80 (+0.64)
Update: Ligand Posts Consecutive Earnings Beat
Trevor Lowenthal - at Seeking Alpha - Tue Oct 28, 3:21PM CDT
LGND: 58.26 (+2.58)
Ligand Pharmaceuticals' (LGND) CEO Steve Holmes on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Oct 27, 1:56PM CDT
LGND: 58.26 (+2.58)
Ligand Pharmaceuticals reaffirms full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:31AM CDT
LGND: 58.26 (+2.58)
Ligand beats Street 3Q forecasts
Automated Insights - Mon Oct 27, 7:16AM CDT
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Monday reported third-quarter net income of $1.3 million.
LGND: 58.26 (+2.58)
Ligand Pharmaceuticals beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 7:07AM CDT
LGND: 58.26 (+2.58)
Ligand Reports Third Quarter 2014 Financial Results
Business Wire - Mon Oct 27, 7:01AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2014, and provided an operating forecast and program updates.
LGND: 58.26 (+2.58)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Oct 26, 4:30PM CDT
ROP: 157.40 (-1.13), SIR: 24.19 (-0.05), VNDA: 12.83 (+0.67), STX: 61.65 (-0.12), NMM: 13.64 (unch), LGND: 58.26 (+2.58), PDS: 7.82 (+0.06), TREX: 44.00 (-0.01), EXAS: 22.59 (-0.01), AWI: 49.17 (unch), EDR: 11.58 (-0.04), HUN: 24.96 (+0.03), TEN: 53.19 (-0.25), AGN: 195.84 (+0.60), ONB: 14.85 (-0.06), STNG: 8.75 (+0.11), MRK: 59.58 (+0.77), BEN: 56.75 (+0.18)
Will Pfizer (PFE) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:20PM CDT
Pfizer (PFE) is scheduled to report third-quarter 2014 results before the opening bell on Oct 28.
VRTX: 117.54 (+0.60), PFE: 30.20 (unch), LGND: 58.26 (+2.58), TEVA: 58.55 (+0.51)
Will Merck (MRK) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:10PM CDT
Merck & Co. Inc. (MRK) is scheduled to report third-quarter 2014 results before the opening bell on Oct 27.
MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), TEVA: 58.55 (+0.51)
Recent News posted below.
Ligand Pharmaceuticals Inc LGND other info.
http://investorshangout.com/Ligand-Pharmaceut...GND-54621/
LGND Ligand Pharmaceuticals Inc Recent Headline News
Shares of LGND Up 13.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - 2 hrs 18 mins ago
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 4 weeks, Ligand Pharmaceuticals has returned 13.91% as of today's recent price of $55.64.
LGND: 58.26 (+2.58)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), ACHN: 13.04 (+0.19), CNAT: 7.06 (unch), MRK: 59.57 (+0.76), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.41 (-0.73)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), ACHN: 13.04 (+0.19), CNAT: 7.06 (unch), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Post Earnings Update: Ligand Pharmaceuticals Has Sunk 0.5% Lower in Past 2 Weeks (LGND)
Comtex SmarTrend(R) - Mon Nov 10, 11:52AM CST
When Ligand Pharmaceuticals (NASDAQ:LGND) reported earnings 14 days ago on October 27th, 2014, analysts, on average, expected the company to report earnings of $0.33 on sales of $14.9 million. The company actually reported EPS of $0.06 on sales of $15.0 million, missing EPS estimates by $0.27 and matching revenue estimates. Shares of Ligand Pharmaceuticals have slipped from $54.23 to $53.94, representing a loss of 0.5%, since the company reported earnings 14 days ago.
LGND: 58.26 (+2.58)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.99 (+0.17), GILD: 108.41 (+1.39), ACHN: 13.04 (+0.19), CNAT: 7.06 (unch), MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), RGLS: 20.41 (-0.50), ABBV: 63.99 (+0.20), BMY: 58.97 (+0.16), ENTA: 43.51 (-0.63)
Ligand Pharmaceuticals Shares Up 12.9% Since SmarTrend's Buy Recommendation (LGND)
Comtex SmarTrend(R) - Mon Nov 03, 10:02AM CST
SmarTrend identified an Uptrend for Ligand Pharmaceuticals (NASDAQ:LGND) on October 17th, 2014 at $48.85. In approximately 2 weeks, Ligand Pharmaceuticals has returned 12.89% as of today's recent price of $55.14.
LGND: 58.26 (+2.58)
Ligand Pharmaceuticals' Shares Fall on Q3 Earnings Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:00PM CDT
Ligand Pharmaceuticals Incorporated (LGND) reported higher third-quarter earnings of 19 cents per share but fell short of the Zacks Consensus Estimate by 2 cents.
BIIB: 326.81 (-1.06), LGND: 58.26 (+2.58), AMGN: 163.25 (+0.16), GSK: 45.80 (+0.64)
Ligand Pharmaceuticals Has Rich A Valuation Now But Is Undervalued For Long Term Success
Chris Katje - at Seeking Alpha - Wed Oct 29, 10:34AM CDT
PFE: 30.20 (unch), AZN: 74.23 (+1.02), LGND: 58.26 (+2.58), AMGN: 163.25 (+0.16), GSK: 45.80 (+0.64)
Update: Ligand Posts Consecutive Earnings Beat
Trevor Lowenthal - at Seeking Alpha - Tue Oct 28, 3:21PM CDT
LGND: 58.26 (+2.58)
Ligand Pharmaceuticals' (LGND) CEO Steve Holmes on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Oct 27, 1:56PM CDT
LGND: 58.26 (+2.58)
Ligand Pharmaceuticals reaffirms full year 2014 guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 8:31AM CDT
LGND: 58.26 (+2.58)
Ligand beats Street 3Q forecasts
Automated Insights - Mon Oct 27, 7:16AM CDT
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Monday reported third-quarter net income of $1.3 million.
LGND: 58.26 (+2.58)
Ligand Pharmaceuticals beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 7:07AM CDT
LGND: 58.26 (+2.58)
Ligand Reports Third Quarter 2014 Financial Results
Business Wire - Mon Oct 27, 7:01AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2014, and provided an operating forecast and program updates.
LGND: 58.26 (+2.58)
Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Oct 26, 4:30PM CDT
ROP: 157.40 (-1.13), SIR: 24.19 (-0.05), VNDA: 12.83 (+0.67), STX: 61.65 (-0.12), NMM: 13.64 (unch), LGND: 58.26 (+2.58), PDS: 7.82 (+0.06), TREX: 44.00 (-0.01), EXAS: 22.59 (-0.01), AWI: 49.17 (unch), EDR: 11.58 (-0.04), HUN: 24.96 (+0.03), TEN: 53.19 (-0.25), AGN: 195.84 (+0.60), ONB: 14.85 (-0.06), STNG: 8.75 (+0.11), MRK: 59.58 (+0.77), BEN: 56.75 (+0.18)
Will Pfizer (PFE) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:20PM CDT
Pfizer (PFE) is scheduled to report third-quarter 2014 results before the opening bell on Oct 28.
VRTX: 117.54 (+0.60), PFE: 30.20 (unch), LGND: 58.26 (+2.58), TEVA: 58.55 (+0.51)
Will Merck (MRK) Pull a Surprise this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 24, 4:10PM CDT
Merck & Co. Inc. (MRK) is scheduled to report third-quarter 2014 results before the opening bell on Oct 27.
MRK: 59.58 (+0.77), LGND: 58.26 (+2.58), TEVA: 58.55 (+0.51)
(0)
(0)